- Home
- NOG vs NAMS Comparison
NOG vs NAMS Comparison
Compare NOG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NOG | NAMS |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NOG | NAMS |
|---|---|---|
| Price | $25.22 | $21.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $31.14 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.44% | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,475,723,000.00 | $22,503,000.00 |
| Revenue This Year | $14.07 | $17.96 |
| Revenue Next Year | $4.24 | $540.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $17.18 | $21.02 |
| 52 Week High | $31.17 | $42.21 |
Technical Indicators
Market Signals| Indicator | NOG | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 32.19 |
| Support Level | $23.28 | N/A |
| Resistance Level | $25.50 | $37.29 |
| Average True Range (ATR) | 0.83 | 1.32 |
| MACD | -0.30 | -0.19 |
| Stochastic Oscillator | 15.83 | 16.63 |
Price Performance
Historical ComparisonAbout NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.